Health-related quality of life trajectory of treatment-naive patients with Merkel cell carcinoma receiving avelumab.

Murtuza Bharmal; Sandra Nolte; Céleste Lebbé; Laurent Mortier; Andrew S. Brohl; Nicola Fazio; Jean-Jacquez Grob; Sara Pusceddu; Glenn J. Hanna; Jessica C. Hassel; Felix Kiecker; Barbara Ellers-Lenz; Marcis Bajars; Gülseren Güzel; Paul Nghiem; Matthias Hunger; Michael Schlichting; Mickaël Henry-Szatkowski; Sandra P. D'Angelo

Health-related quality of life trajectory of treatment-naive patients with Merkel cell carcinoma receiving avelumab.

Murtuza Bharmal, Sandra Nolte, Céleste Lebbé, Laurent Mortier, Andrew S. Brohl, Nicola Fazio, Jean-Jacquez Grob, Sara Pusceddu, Glenn J. Hanna, Jessica C. Hassel, Felix Kiecker, Barbara Ellers-Lenz, Marcis Bajars, Gülseren Güzel, Paul Nghiem, Matthias Hunger, Michael Schlichting, Mickaël Henry-Szatkowski, Sandra P. D'Angelo

Research output: Contribution to journal › Article › peer-review

Abstract

Aim: To evaluate changes in health-related quality of life (HRQoL) in a Phase II trial (NCT02155647) of treatment-naive patients with metastatic Merkel cell carcinoma treated with avelumab (15-month follow-up). Materials methods: Mixed-effect Models for Repeated Measures were applied to HRQoL data (FACT-M; EQ-5D-5L) to assess changes over time. Clinically derived progression-free survival was compared with HRQoL deterioration-free survival. Results: Overall, we saw relative stability in HRQoL among 116 included patients, with nonprogression associated with statistically and clinically meaningful better HRQoL compared with progressive disease. Deterioration-free survival rates (49-72 months, 40-582 months) were consistently higher/better compared with progression-free survival rates (41/31/12 months). Conclusion: These findings show unique longitudinal HRQoL data for treatment-naive metastatic Merkel cell carcinoma patients treated with avelumab. Clinical trial registration: NCT02155647 (ClinicalTrials.gov).

Original language	English
Journal	Future Oncology
Issue number	27
Publication status	Published - Sep 1 2020

Cite this

Bharmal, M., Nolte, S., Lebbé, C., Mortier, L., Brohl, A. S., Fazio, N., Grob, J-J., Pusceddu, S., Hanna, G. J., Hassel, J. C., Kiecker, F., Ellers-Lenz, B., Bajars, M., Güzel, G., Nghiem, P., Hunger, M., Schlichting, M., Henry-Szatkowski, M., & D'Angelo, S. P. (2020). Health-related quality of life trajectory of treatment-naive patients with Merkel cell carcinoma receiving avelumab. Future Oncology, (27).

Health-related quality of life trajectory of treatment-naive patients with Merkel cell carcinoma receiving avelumab. / Bharmal, Murtuza; Nolte, Sandra; Lebbé, Céleste; Mortier, Laurent; Brohl, Andrew S.; Fazio, Nicola; Grob, Jean-Jacquez; Pusceddu, Sara; Hanna, Glenn J.; Hassel, Jessica C.; Kiecker, Felix; Ellers-Lenz, Barbara; Bajars, Marcis; Güzel, Gülseren; Nghiem, Paul; Hunger, Matthias; Schlichting, Michael; Henry-Szatkowski, Mickaël; D'Angelo, Sandra P.

In: Future Oncology, No. 27, 01.09.2020.

Research output: Contribution to journal › Article › peer-review

Bharmal, M, Nolte, S, Lebbé, C, Mortier, L, Brohl, AS, Fazio, N, Grob, J-J, Pusceddu, S, Hanna, GJ, Hassel, JC, Kiecker, F, Ellers-Lenz, B, Bajars, M, Güzel, G, Nghiem, P, Hunger, M, Schlichting, M, Henry-Szatkowski, M & D'Angelo, SP 2020, 'Health-related quality of life trajectory of treatment-naive patients with Merkel cell carcinoma receiving avelumab.', Future Oncology, no. 27.

Bharmal, Murtuza ; Nolte, Sandra ; Lebbé, Céleste ; Mortier, Laurent ; Brohl, Andrew S. ; Fazio, Nicola ; Grob, Jean-Jacquez ; Pusceddu, Sara ; Hanna, Glenn J. ; Hassel, Jessica C. ; Kiecker, Felix ; Ellers-Lenz, Barbara ; Bajars, Marcis ; Güzel, Gülseren ; Nghiem, Paul ; Hunger, Matthias ; Schlichting, Michael ; Henry-Szatkowski, Mickaël ; D'Angelo, Sandra P. / Health-related quality of life trajectory of treatment-naive patients with Merkel cell carcinoma receiving avelumab. In: Future Oncology. 2020 ; No. 27.

@article{ecd6f7e57eb04093aa648c91f47b0c67,

title = "Health-related quality of life trajectory of treatment-naive patients with Merkel cell carcinoma receiving avelumab.",

abstract = "Aim: To evaluate changes in health-related quality of life (HRQoL) in a Phase II trial (NCT02155647) of treatment-naive patients with metastatic Merkel cell carcinoma treated with avelumab (15-month follow-up). Materials methods: Mixed-effect Models for Repeated Measures were applied to HRQoL data (FACT-M; EQ-5D-5L) to assess changes over time. Clinically derived progression-free survival was compared with HRQoL deterioration-free survival. Results: Overall, we saw relative stability in HRQoL among 116 included patients, with nonprogression associated with statistically and clinically meaningful better HRQoL compared with progressive disease. Deterioration-free survival rates (49-72 months, 40-582 months) were consistently higher/better compared with progression-free survival rates (41/31/12 months). Conclusion: These findings show unique longitudinal HRQoL data for treatment-naive metastatic Merkel cell carcinoma patients treated with avelumab. Clinical trial registration: NCT02155647 (ClinicalTrials.gov).",

author = "Murtuza Bharmal and Sandra Nolte and C{\'e}leste Lebb{\'e} and Laurent Mortier and Brohl, {Andrew S.} and Nicola Fazio and Jean-Jacquez Grob and Sara Pusceddu and Hanna, {Glenn J.} and Hassel, {Jessica C.} and Felix Kiecker and Barbara Ellers-Lenz and Marcis Bajars and G{\"u}lseren G{\"u}zel and Paul Nghiem and Matthias Hunger and Michael Schlichting and Micka{\"e}l Henry-Szatkowski and D'Angelo, {Sandra P.}",

note = "Place: England",

year = "2020",

month = sep,

day = "1",

language = "English",

journal = "Future Oncology",

issn = "1479-6694",

publisher = "Future Medicine Ltd.",

number = "27",

}

TY - JOUR

T1 - Health-related quality of life trajectory of treatment-naive patients with Merkel cell carcinoma receiving avelumab.

AU - Bharmal, Murtuza

AU - Nolte, Sandra

AU - Lebbé, Céleste

AU - Mortier, Laurent

AU - Brohl, Andrew S.

AU - Fazio, Nicola

AU - Grob, Jean-Jacquez

AU - Pusceddu, Sara

AU - Hanna, Glenn J.

AU - Hassel, Jessica C.

AU - Kiecker, Felix

AU - Ellers-Lenz, Barbara

AU - Bajars, Marcis

AU - Güzel, Gülseren

AU - Nghiem, Paul

AU - Hunger, Matthias

AU - Schlichting, Michael

AU - Henry-Szatkowski, Mickaël

AU - D'Angelo, Sandra P.

N1 - Place: England

PY - 2020/9/1

Y1 - 2020/9/1

N2 - Aim: To evaluate changes in health-related quality of life (HRQoL) in a Phase II trial (NCT02155647) of treatment-naive patients with metastatic Merkel cell carcinoma treated with avelumab (15-month follow-up). Materials methods: Mixed-effect Models for Repeated Measures were applied to HRQoL data (FACT-M; EQ-5D-5L) to assess changes over time. Clinically derived progression-free survival was compared with HRQoL deterioration-free survival. Results: Overall, we saw relative stability in HRQoL among 116 included patients, with nonprogression associated with statistically and clinically meaningful better HRQoL compared with progressive disease. Deterioration-free survival rates (49-72 months, 40-582 months) were consistently higher/better compared with progression-free survival rates (41/31/12 months). Conclusion: These findings show unique longitudinal HRQoL data for treatment-naive metastatic Merkel cell carcinoma patients treated with avelumab. Clinical trial registration: NCT02155647 (ClinicalTrials.gov).

AB - Aim: To evaluate changes in health-related quality of life (HRQoL) in a Phase II trial (NCT02155647) of treatment-naive patients with metastatic Merkel cell carcinoma treated with avelumab (15-month follow-up). Materials methods: Mixed-effect Models for Repeated Measures were applied to HRQoL data (FACT-M; EQ-5D-5L) to assess changes over time. Clinically derived progression-free survival was compared with HRQoL deterioration-free survival. Results: Overall, we saw relative stability in HRQoL among 116 included patients, with nonprogression associated with statistically and clinically meaningful better HRQoL compared with progressive disease. Deterioration-free survival rates (49-72 months, 40-582 months) were consistently higher/better compared with progression-free survival rates (41/31/12 months). Conclusion: These findings show unique longitudinal HRQoL data for treatment-naive metastatic Merkel cell carcinoma patients treated with avelumab. Clinical trial registration: NCT02155647 (ClinicalTrials.gov).

M3 - Article

JO - Future Oncology

JF - Future Oncology

SN - 1479-6694

IS - 27

ER -

Health-related quality of life trajectory of treatment-naive patients with Merkel cell carcinoma receiving avelumab.

Abstract

Fingerprint

Cite this